We assessed the occurrence of oculo-respiratory syndrome (ORS) following two influenza vaccines: Fluviral (Shire Biologics) or Vaxigrip (Aventis Pasteur). ORS was identified amongst 5.3 and 4.6% of recipients, respectively (P=0.54). With both vaccines, the risk of ORS was much greater in individuals who had ORS the previous year (2000) than in those without such history. In multivariate analysis, the odds ratio for ORS for patients with a prior history of ORS varied between 9.4 and 9.6 (P<0.001) whereas that comparing Fluviral and Vaxigrip varied between 1.5 and 1.9 (P=0.02-0.05). ORS is an adverse event that is present with more than one vaccine and may be present with any influenza vaccines to a greater or lesser degree.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0264-410x(03)00095-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Canadian vaccine safety surveillance reports following immunization with seasonal influenza vaccines, 2021-2022.
Can Commun Dis Rep
January 2024
Centre for Immunization Surveillance, Infectious Diseases and Vaccination Programs Branch, Public Health Agency of Canada, Ottawa, ON.
Background: Seasonal influenza vaccines (SIV) authorized for use in Canada have all undergone rigorous regulatory assessments for safety and effectiveness. Serious adverse events following immunization (AEFI) can occur, though they are rare. Continuous safety surveillance of vaccines during the post-marketing phase is a critical component of vaccination programs.
View Article and Find Full Text PDFSummary of the National Advisory Committee on Immunization (NACI) Statement on Seasonal Influenza Vaccine for 2015-2016.
Can Commun Dis Rep
October 2015
Chair, NACI.
Background: The National Advisory Committee on Immunization (NACI) provides the Public Health Agency of Canada with ongoing and timely medical, scientific, and public health advice relating to immunization.
Objective: To summarize the update of the 2015-2016 recommendations by NACI regarding the use of seasonal influenza vaccines.
Methods: Annual influenza vaccine recommendations are developed by the Influenza Working Group for consideration by NACI, based on NACI's evidence-based process for developing recommendations, and includes: a consideration of the burden of influenza illness and the target populations for vaccination; efficacy and effectiveness, immunogenicity, and safety of influenza vaccines; vaccine schedules; and other aspects of influenza immunization.
Oculo-respiratory syndrome after influenza vaccination: trends over four influenza seasons.
Vaccine
May 2005
Institut National de Santé Publique du Québec, Canada.
Background: Oculo-respiratory syndrome (ORS) following influenza vaccination was identified in Canada in 2000. This report describes trends of ORS reported during four consecutive seasons 2000, 2001, 2002 and 2003 in the province of Quebec, Canada.
Methods: Data come from the vaccine-associated adverse event (VAAE) passive reporting system of the Province of Quebec.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!